Optimer's fidaxomicin filing accepted in EU
This article was originally published in Scrip
Executive Summary
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.